Navigation Links


Cancer in Biological Technology

Viral Genetics Creates Subsidiary to Develop Cancer Therapy

... in animal studies to not only directly cause cancer cells to die but also to synergize with existing ... disruption is a concept that has tantalized cancer researchers for decades. We believe that we ... the senior director for infectious disease and cancer at Hollis Eden Pharmaceuticals. He served as ...

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

... novel antibody therapeutics that target cancer stem cells, today announced the publication in ... potent anti-cancer activity in colon and breast cancer models for the company's first product candidate, ... the therapeutic potential of targeting cancer stem cells to treat solid tumors. OMP-21M18 is ...

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

... on developing proprietary targeted medicines for cancer treatment and Debiopharm Group (Debiopharm), a ... we believe may offer future benefit to cancer patients," said Dan Passeri, Curis President and ... basal cell carcinoma, metastatic colorectal cancer and advanced ovarian cancer," said Michael Gray, ...

The Breast Cancer Therapeutics Market in Australia

... /PRNewswire/ -- Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia. As the most common cancer diagnosed in Australia's female population, the ...

TSH Testing Raises Awareness of Importance of Thyroid Health

... in the U.S. even though the rate of thyroid cancer has nearly tripled since 1980," said Joseph ... four counties neighboring Indian Point, thyroid cancer is 70% above the U.S. rate and newborn ... a damaged thyroid can be." "The National cancer Institute is looking at Iodine 131, the most ...

ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery

... Plc (SCLP.PL), which is developing therapeutic cancer and infectious disease vaccines. This research ... and strategic partnering to develop therapeutic cancer and infection disease vaccines. In 2008, Pfizer ... novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its ...

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

... picoplatin data from our colorectal and prostate cancer programs. These data further enhance the value ... 3 SPEAR trial of picoplatin in small cell lung cancer in the fourth quarter of 2009 with the goal of ... of this year. Colorectal cancer (CRC) : Presented new progression-free survival ...

Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress

... Product revenue from the Onco type DX(R) breast cancer test was $35.2 million in the second quarter of ... type DX access and coverage to a broader breast cancer population," said Kim Popovits, President and ... Onco type DX to more than 100,000 breast cancer patients and today remain on track to make our ...

Oncothyreon appoints Diana Hausman as Vice President of Clinical Development

... "Her leadership and knowledge of all aspects of cancer drug development will be very important as we ... at an exciting target at the forefront of current cancer drug research." Dr. Hausman joins Oncothyreon ... potential to improve the lives and outcomes of cancer patients. For more information, visit ...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... GVHD, a common disorder among immunocompromised cancer patients after receiving allogeneic stem cell or ... clinical trial conducted at the Fred Hutchinson cancer Research Center. The second trial was a ... to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, ...

W.M. Keck Foundation Awards $1 Million to Hutchinson Center Scholar to Study How Cells Go Awry

... /PRNewswire/ -- Anyone touched by the ravages of cancer knows the rapidly growing, opportunistic cells don't play fair. But in order to expose exactly how cancer cells cheat their host, scientists must first ... - which enhances the potential for learning how cancer cells cheat - Fred ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... a patient's T cells to seek out and destroy cancer cells. In June, Micromet announced that ... regimens, but retained a detectable level of ALL cancer cells in their bone marrow - so called minimal ... T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are ...

Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer

... of Lung Cancer's 13th World Conference on Lung cancer in San Francisco on August 1, 2009. The presentation by Dr. Glenwood Goss from the Ottawa Hospital cancer Centre, Ottawa, Ontario, involved 16 patients who ... patients with stage IIIb/IV non-small cell lung cancer (NSCLC). As of the time of data analysis in ...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

... About Multiple Myeloma Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable ... hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the ...

CuraGen Reports Second Quarter 2009 Financial Results

... the development opportunities for CR011 in breast cancer and melanoma," commented Dr. Timothy M. Shannon, ... forward to presenting updated data for the breast cancer study in the second half of 2009." In ... development opportunities for CR011 in breast cancer and melanoma and the expected timing for ...

Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference

... developer of oncology compounds directed to cancer stem cell targets, today announced that the ... been invited to present at the New Frontiers in cancer Drug Development conference which is part of ... entitled "Developing Drug Candidates Directed to cancer Stem Cell Targets: Preclinical and Clinical ...

Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results

... a patient with progressive breast cancer who experienced a PR (34% shrinkage in ... the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program ... belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the ...

Sunesis Reports Financial Results for the Second Quarter 2009

... in women with platinum-resistant ovarian cancer were also presented at the ASCO 2009 Annual ... Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled ... for new treatment options. About Ovarian cancer In the United States, ...

Sanofi-aventis Announces Second Quarter 2009 Results

... 584 million, driven by its use in adjuvant breast cancer treatment and in prostate cancer. Growth was good ... 34 million, boosted in particular by the prostate cancer indication approved in the second half of 2008. ... , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as a first-line ...

Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4

... profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome ... in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. ... include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and ...

NeoGenomics Reports Second Quarter 2009 Results

... capability to perform a portion of their bladder cancer FISH testing in-house while simultaneously ... As a result, revenue from this customer's bladder cancer FISH testing declined by $278,000 in Q2 09 ... to have the opportunity to develop certain other cancer tests over time, and to have Abbott as new 9.6% ...

Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)

... the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program ... belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and ... projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of ...

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

... a post approval study of MuGard in head and neck cancer patients undergoing radiation treatment in the UK ... undergoing radiation treatment for head and neck cancer experience some level of oral mucositis. This ... patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation ...

Biomodels Expands Efforts in Cancer Supportive Care, Pulmonary Fibrosis; Preclinical Research Organization Names Dr. Stephen T. Sonis as Partner

... it will further increase its work in the areas of cancer supportive care, pulmonary fibrosis, and ... expert in the clinical treatment and research of cancer regimen-related mucosal toxicities, said the ... and biotechnology clients in the area of cancer supportive care is expected to grow sharply this ...

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

... programs highlighted by our bavituximab Phase II cancer program, which is already generating promising ... in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product ...

NewLink Genetics Corporation Closes $7.5 Million Financing

... the clinical development of its therapeutic cancer products. This financing involved additional ... one of the leaders in the expanding field of cancer immunotherapy," said Dr. Charles Link, Chairman ... our lead immunotherapy product for pancreatic cancer into pivotal clinical studies and to advance our ...

Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)

... the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program ... belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and ... projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of ...

Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing

... "This technology should change the way in which cancer drugs are developed." For more ... these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its ...

Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies

... of Eisai Corporation of North America, and cancer Innovations, Inc. (CII), a privately held ... with potential applications in the treatment of cancer and neo-vascular disorders," said Toni Gray, ... therapeutic applications. About cancer Innovations, Inc. ...

Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting

... the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program ... belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and ... projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of ...

University of Florida Shands Cancer Center Selects OnCore(r) to Support its Collaborative Research Goals

... decision by the University of Florida Shands cancer Center (UFSCC) to select OnCore(r) products in ... of the contract, the UFSCC has become the 25th cancer center to adopt the OnCore platform. ... decision by the University of Florida Shands cancer Center (UFSCC) to select OnCore(r) products in ...

Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009

... has now received all the remaining six novel cancer drug candidates from Santaris Pharma and Enzon ... associated with schizophrenia. Clin cancer Research In January 2009 Santaris Pharma ... suppressive microRNAs in lung cancer. cancer Research In January 2009 Santaris Pharma ...

ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens

... into an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen ... platform to develop DPX-0907, a therapeutic cancer vaccine. Within the next six months the company ... licensing agreement significantly advances our cancer immunotherapy capabilities and represents our ...

Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial

... focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell ... of its immunotherapy on 27 Stage IV breast cancer patients who have failed conventional therapy. ...

USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk

... University Hospital and USC Kenneth Norris, Jr. cancer Hospital at the University of Southern ... University Hospital and USC Kenneth Norris, Jr. cancer Hospital will continue to use the Quantros Safety ... teaching hospital closely aligned with USC Norris cancer Hospital and staffed by the faculty of USC's Keck ...

First Catalog Cancer Biochip for Sequence Capture Now Available from febit

... announced today the launch of the first human cancer biochip for HybSelect, febit's highly automated ... Next-Generation Sequencing (NGS). The new catalog cancer biochip features 115 important genes which are reported to be associated with common types of cancer by the Wellcome Trust Sanger Institute. ...

Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer

... and survival in patients with metastatic breast cancer (MBC), according to a newly published report in ... blood. "Measuring CTCs in metastatic breast cancer patients provides oncologists with an additional ... at The University of Texas M. D. Anderson cancer Center. "The CellSearch(R) CTC test provides an ...

MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus

... immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, was awarded a $50 ... of novel biologics for autoimmune disorders, cancer and infectious diseases. Since its founding in ... three proprietary technology platforms: (1) cancer stem-like cells; (2) Dual Affinity Re-Targeting ...

Johnson & Johnson Completes Acquisition of Cougar Biotechnology

... with metastatic, castration-resistant prostate cancer who have progressed after docetaxel-based ... with metastatic, castration-resistant prostate cancer who have yet to receive chemotherapy. One in six men will be diagnosed with prostate cancer in his lifetime, and the disease accounts for 10 ...

OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance

... to serve as a positive resource to help so many cancer patients obtain lifesaving treatments," says ... the $10 million mark in November 2008. cancer imposes heavy economic burdens on patients and ... in need of financial assistance while undergoing cancer care simply because of the high cost of care." ...
Other Contentsendospermendosymbiosisendosymbiosisendothermentropyentropyenvironmentenvironmentenvironmentenvironmentenvironmentenvironmentenvironmentenvironmentenvironment
(Date:11/9/2009)...ction method that begins by soaking corn kernels r...of ethanol and more usable co-products, giving eth...out 20 percent. , "The conventional ethanol prod...illers dried grains with soluble, it doesn,t have ...s Agricultural Engineer Esha Khullar. "Whereas in ...
(Date:11/9/2009)...ogists David Queller and Joan Strassmann argue in ... between components, from the genetic level on up,...that thing is an animal, a plant, a bacteria or a...describe an organism, such as individuality or eve...sary to achieve organismality. What is necessary, ...
(Date:11/9/2009)...9, 2009 / b3c newswire / - Today, TNO, a Dutch ...an American organization for contract research and...ned a letter of intent with regard to TNOs dynamic...r of intent proposes a collaboration in which Seve...lization in North America. The TIM systems will be...
Breaking Biology News(10 mins):Wet ethanol production process yields more ethanol and more co-products 2What is the meaning of 'one'? 2What is the meaning of 'one'? 3TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2SK Life Sciences has Licensed Pristima 13368 1SK Life Sciences has Licensed Pristima 13368 2New Book Helps Those with Bipolar Disorder Manage Diets and Lives 53692 1New Book Helps Those with Bipolar Disorder Manage Diets and Lives 53692 2Andrew Allen joins Navvis 26amp 3B Company 53689 1Andrew Allen joins Navvis 26amp 3B Company 53689 2
(Date:11/9/2009)...ighlighting a commitment to providing long-term he...and digital display technology options, LG Electro...ospital Grade LCD HDTVs this week at the Associati... meeting and exposition (booth #1760). ,, On di...M)" Long-Term Care LCD HDTVs bring a sense of home...
(Date:11/9/2009)...om incapacitated to working again, , ,...imulation of a certain area of the brain may prove... German researchers. , They implanted electrode...0 people. This area of the brain is part of the r...d experiences and puts them in a state of pleasant...
(Date:11/9/2009)...Newswire/ -- Speaker Nancy Pelosi released the fo...dable Health Care for America Act (H.R. 3962) ...dicare Part D costs for people living with HIV/AID...e of 220 to 215: ,, "Effective drug treatments... thousands of Americans living with HIV/AIDS. Howe...
(Date:11/9/2009)...wire/ -- At a time when the 250,000+ eligible Medi...d about finding affordable health insurance, they ..., The Today,s Options® Preferred Provider ...s a cost-effective and comprehensive alternative t... People with Medicare can choose to sign up for t...
(Date:11/9/2009)...Newswire/ -- The American Academy of Physician Ass...ically practicing physician assistants (PAs) pract...e of Representatives for passing Saturday its heal...lth Care for America Act. ,, "We are especially...ower the cost of health care and greatly expand co...
Breaking Medicine News(10 mins):Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 2Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 3Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 5Health News:Brain Stimulation May Ease Treatment-Resistant Depression 2Health News:Pelosi Applauds Provisions in Health Bill to Improve Access to Care, Medications for People Living With HIV/AIDS 2Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2Health News:American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill 2
Other TagsCharitCauteryTempTempTempTempTempTempLovLovLovLovCoagulatorRetainingOther Tagspathologist 2veterinary 2veterinary 3veterinary 4veterinary 5veterinary 6veterinary 7imaging 2imaging 3imaging 4imaging 5imaging 6imaging 7imaging 8imaging 9imaging 10aging 2aging 3aging 4aging 5aging 6clues 2clues 3clues 4clues 5clues 6clues 7clues 8clues 9clues 10yields 2yields 3yields 4worms 2worms 3worms 4completed 2completed 3completed 4completed 5completed 6completed 7completed 8